Yahoo · Oct 14, 2026
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.
NASDAQ · TMO
Thermo Fisher Scientific Inc.
Healthcare · Medical - Diagnostics & Research
$663.04
Up+$11.29 (+1.70%)
Updated Oct 14, 2026, 5:29 PM
SID Score
7.1/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 219.39B
- P/E ratio
- 33.3
- Dividend yield
- 0.32%
- 52-week range
- $435.27 – $694.33
- Volume
- 2.3M
- Avg. volume
- 2.05M
Price performance · TMO
TMO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
TMO closed at $663.04 after 21 trading sessions, up 3.38% for the selected period.
- Last close
- $663.04
- Period change
- +3.38%
- Period low
- $641.39
- Period high
- $679.61
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $662.84 | $666.38 | $655.73 | $663.04 | 2.3M |
| Oct 12, 2026 | $657.23 | $662.54 | $652.5001 | $662.24 | 1.38M |
| Oct 9, 2026 | $650.00 | $661.94 | $644.1605 | $658.02 | 1.58M |
| Oct 8, 2026 | $657.53 | $658.56 | $635.32 | $651.98 | 2.59M |
| Oct 7, 2026 | $662.40 | $671.665 | $651.12 | $662.06 | 1.83M |
| Oct 6, 2026 | $683.35 | $694.325 | $654.51 | $656.58 | 2.75M |
| Oct 5, 2026 | $648.04 | $676.76 | $648.04 | $676.76 | 2.12M |
| Oct 2, 2026 | $654.15 | $659.47 | $648.29 | $654.80 | 1.67M |
| Oct 1, 2026 | $672.39 | $673.12 | $651.77 | $652.51 | 2.38M |
| Sep 30, 2026 | $675.95 | $683.63 | $671.63 | $675.05 | 2.32M |
| Sep 29, 2026 | $676.42 | $681.38 | $670.895 | $679.61 | 1.85M |
| Sep 28, 2026 | $668.02 | $682.61 | $664.23 | $678.60 | 1.91M |
| Sep 25, 2026 | $677.53 | $678.00 | $664.53 | $675.00 | 2.1M |
| Sep 24, 2026 | $660.91 | $682.98 | $655.95 | $678.39 | 2.1M |
| Sep 23, 2026 | $657.61 | $671.47 | $655.7803 | $665.30 | 2.35M |
| Sep 22, 2026 | $656.41 | $662.87 | $651.54 | $658.52 | 2.11M |
| Sep 21, 2026 | $653.89 | $660.44 | $649.1201 | $658.76 | 2.3M |
| Sep 18, 2026 | $656.61 | $660.10 | $646.805 | $651.45 | 4.58M |
| Sep 17, 2026 | $656.75 | $663.57 | $649.00 | $658.32 | 4.2M |
| Sep 16, 2026 | $642.00 | $653.40 | $638.00 | $648.43 | 2.88M |
| Sep 15, 2026 | $615.47 | $641.97 | $613.95 | $641.39 | 3.02M |
Latest TMO news
The latest Smart Investors Daily articles mentioning TMO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TMO research
Overview
Company profile and research snapshot.
Company profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $625.78
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Buy | — |
| Oct 13, 2026 | Morgan Stanley | Overweight | — |
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 3, 2026 | CLSA | Outperform | — |
| Jul 27, 2026 | Morgan Stanley | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 14, 2026
Global 3D Cell Culture Technologies Market Report 2026-2030 | Capitalize on 19.9% CAGR as Merck KGaA, Corning, Thermo Fisher Scientific, Sartorius, and Lonza Scale Organoids
Boost ROI with scalable, high-throughput 3D platforms that cut variability and per-sample costs, maximize limited cells, and localize production to offset tariffs.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "3D Cell Culture Technologies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global 3D cell culture technologies market is experiencing rapid expansion, supported by growing pharmaceutical research, increased investment in regenerative medicine, and demand for more
Yahoo · Oct 14, 2026
Global Metabolomics Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 17.3% CAGR as Thermo Fisher, Bruker, Agilent, and Metabolon Accelerate AI Diagnostics
Players: Metabolon, Bruker, Agilent, Thermo Fisher and Waters. Profiles cover products, services, market share, segments, trends, opportunities and regional presence.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Metabolomics Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global metabolomics market is experiencing rapid expansion, driven by advances in biomarker discovery, personalized medicine, cancer research and analytical technologies. The market grew from $4.17 bil
Yahoo · Oct 14, 2026
Global Flow Cytometry Market Report 2026 | Capitalize on 11.3% CAGR as Beckman Coulter, Thermo Fisher, Cytek, and Bio-Rad Scale AI Automation and Precision Medicine
Boost ROI through automated sample prep, AI analytics, high-throughput testing, portfolio expansion via acquisitions, and regional production to reduce tariff exposure.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Flow Cytometry Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global flow cytometry market is experiencing rapid growth, supported by increasing biomedical research, expanding cancer diagnostics, greater availability of advanced cytometers and rising investme
AI research layers
Interpretive context generated from the platform’s current data sources.
Thermo Fisher Scientific Inc. Stock Performance
Thermo Fisher Scientific Inc. shares closed at $663.04, reflecting a daily decline of approximately 1.05%, per SID market data. Despite this pullback, the stock has demonstrated positive momentum across multiple timeframes, gaining 8.6% over the past month, 24.0% over three months, and 14.35% over the trailing twelve months. TMO currently trades well above both its 50-day moving average of $628.17 and its 200-day moving average of $533.05, indicating sustained upward trend strength according to Massive/Polygon technical data. The 14-day relative strength index sits at 51.5, placing the stock in neutral territory with no immediate overbought or oversold signals. Average daily trading volume stands at approximately 2.05 million shares, supporting consistent liquidity. The stock carries a beta of 0.902, suggesting slightly lower volatility relative to the broader market, consistent with its positioning within the healthcare sector.
Thermo Fisher Scientific Inc. Valuation Analysis
Thermo Fisher Scientific commands a market capitalization of approximately $219.4 billion, making it one of the largest companies in the healthcare sector, per SID market data. The stock trades at a price-to-earnings ratio of 33.3, reflecting a premium valuation relative to broader market averages, while its price-to-book ratio stands at 4.29, according to SEC filings. The PEG ratio registers at an elevated 577.2, suggesting that the current earnings multiple is significantly high relative to near-term projected earnings growth rates. TMO offers a modest dividend yield of approximately 0.29%, indicating the company prioritizes reinvestment and capital allocation strategies over shareholder distributions. This valuation profile positions Thermo Fisher as a premium-priced healthcare name where investors are paying for the company's established market leadership, diversified life sciences portfolio, and long-term growth runway rather than near-term earnings acceleration.
Smart Money Activity for TMO
Thermo Fisher Scientific's composite smart money score stands at 46 out of 100 with a neutral signal, per SID market data. Institutional positioning represents the strongest component at a perfect 25 out of 25, reflecting robust conviction among major fund managers and asset allocators. In contrast, insider activity scores 9.5 out of 25, with SEC Form 4 filings revealing 20 insider transactions over the past 90 days, comprising 6 purchases and 14 sales. This sell-heavy insider ratio suggests executives and directors have been net reducers of their holdings during the recent price appreciation. Dark pool activity registers at 8.5 out of 25, indicating below-average levels of off-exchange institutional accumulation, according to 13F institutional filings. Congressional trading activity scores just 3.2 out of 25, showing minimal legislative interest. The divergence between strong institutional ownership and weaker insider sentiment creates a mixed signal profile for prospective investors evaluating smart money trends in TMO shares.
Thermo Fisher Scientific Inc. Earnings Outlook
Thermo Fisher Scientific has delivered consecutive earnings beats in its two most recently reported quarters, according to company earnings reports. In the quarter reported on April 23, 2026, the company posted earnings per share of $5.44, exceeding the consensus estimate of $5.23 by $0.21, representing a 4.0% positive surprise. The subsequent quarter reported on July 23, 2026, showed further improvement with EPS of $6.03 versus analyst expectations of $5.71, delivering a $0.32 beat. Looking ahead, analysts estimate earnings of $5.71 per share for the quarter with results expected on July 22, 2026, and $6.40 per share for the quarter scheduled for October 21, 2026, per analyst estimates. The sequential increase in consensus estimates from $5.71 to $6.40 reflects expectations for continued earnings growth. Thermo Fisher's recent track record of outperformance against consensus provides context for evaluating these forward projections.
Wall Street Analyst Ratings for TMO
Wall Street sentiment toward Thermo Fisher Scientific remains predominantly constructive, with recent analyst actions skewing toward bullish designations, per Wall Street analyst reports. On October 7, 2026, Barclays maintained its Overweight rating, marking the firm's third consecutive reaffirmation of this positive stance during the review period. CLSA initiated coverage on September 3, 2026, with an Outperform rating, adding a fresh bullish voice to the coverage universe. Morgan Stanley similarly maintained its Overweight rating on July 27, 2026, reinforcing institutional confidence in TMO's trajectory. Piper Sandler represents the lone neutral voice among recent ratings, maintaining its Neutral designation on July 27, 2026, according to SID consensus data. Of the five most recent analyst actions tracked, four carry bullish-equivalent ratings while one remains neutral, with no underperform or sell-equivalent ratings present. No analyst downgrades have been recorded in the recent period, indicating stable-to-positive professional sentiment across the coverage base.
